Guth MAS. Implementing 212 Pb-Targeted Alpha Therapy: A Safety-First Theranostic Framework for Clinical Practice. Clin Nucl Med Open. 2026;3(3):DOI: 10.1097/nm9.0000000000000092.
Table 1. Target-Specific Organs at Risk and Mitigation Strategies for Pb-212-TAT and FAP-Targeted Analogs
| Organ/Tissue | SSTR2/FAP Expression | Primary Radiation Risk | Proactive Mitigation and Monitoring Strategy |
| Pituitary Gland | High (SUVmax ≈ 15–25) | Hypopituitarism (central hypothyroidism, hypogonadism, adrenal insufficiency) | Pre-Tx: Quantify Tumor-to-Pituitary SUV ratio. Dosimetry: Establish/respect absorbed dose limit (e.g., < 15 Gy). Monitoring: Baseline and annual pituitary axis panel (TSH/fT4, morning cortisol, testosterone/estradiol, LH/FSH) for ≥ 10 years. |
| Bone Marrow | Low (progenitor cell subsets) | Cytopenias; Therapy-Related Myeloid Neoplasms (t-MDS/AML) | Dosimetry: Apply red marrow absorbed dose constraints. Monitoring: Pre-cycle CBC with differential; annual CBC and peripheral blood smear for ≥ 5–10 years post-therapy. |
| Kidneys | Very Low | Chronic nephropathy | Mitigation: Mandatory renoprotective amino acid infusion during therapy. Monitoring: Baseline and annual serum creatinine / eGFR. |
| Vasculature (FAP-specific) | Atherosclerotic plaques | Plaque Instability / Accelerated Atherosclerosis | Imaging: Baseline FAPI-PET screening for vascular ‘hot spots’ to quantify atherosclerotic burden. Exclusion: Consider exclusion of patients with diffuse vascular uptake (e.g., SUVmax > 10 in major vessels) pending safety data. |
| Lungs (FAP-specific) | Fibrotic tissues (IPF) | Radiation-induced pneumonitis / Exacerbation of fibrosis | Pre-Tx: Detailed respiratory history; consider high-resolution chest CT if clinically indicated. Monitoring: Baseline and periodic pulmonary function tests (PFTs) in patients with known interstitial lung disease or significant FAPI uptake in lung parenchyma. |
| Liver (FAP-specific) | Cirrhosis / Fibrosis | Radiation-induced liver disease (RILD); Hepatic failure | Pre-Tx: Baseline LFTs and FibroScan (stiffness). Imaging: FAPI-PET to assess “background” hepatic uptake. |
| Joints (FAP-specific) | Activated Synovium (RA/OA) | Synovitis / Radiation-induced joint inflammation | Pre-Tx: Detailed history of inflammatory arthropathy; consider rheumatology consultation for patients with active RA/OA. Monitoring: Assessment of joint pain/swelling post-therapy in patients with high baseline joint uptake on FAPI-PET. |
| Uterus (FAP-specific) | Gravid Uterine Stroma | Fetal radiation exposure | Exclusion: Mandatory pregnancy testing; highly effective contraception protocols per radiopharmaceutical clinical trial standards. |
| Other Endocrine Tissues | Pancreatic Islets (Alpha cells), Thyroid | Subclinical dysfunction / Metabolic effects | Monitoring: Consider baseline and periodic assessment of glucose metabolism (HbA1c) and thyroid function (TSH). |
Posted in